Roivant prices $150M primary/secondary offering at $5.00 per share

Roivant Sciences Ltd.

Company sold 20M shares for ~$100M gross; selling shareholders sold 10M for ~$50M; $5.00/share.
Underwriter granted 30-day option to purchase up to $22.5M additional common shares.
Roivant expects cash position to fund operations into H2 2025; proceeds not received from selling shareholders.
Offering closed on Nov 10, 2022; sole bookrunner Cantor Fitzgerald.
Registration statement effective Oct 3, 2022; prospectus supplement filed Nov 8.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Roivant Sciences Ltd. entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at $150 million (effective 2022-11-08).

Action: entry
Agreement: underwriting
Counterparty: Cantor Fitzgerald & Co.
Value: $150 million
Effective: 2022-11-08

Exact text from the filing

On November 8, 2022, Roivant Sciences Ltd. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (the “Underwriter”), as the sole underwriter, and the selling shareholders named therein (the “Selling Shareholders”) relating to the issuance and sale in an underwritten offering (the “Offering”) of 30,000,000 (the “Shares”) of the Company’s common shares, par value $0.0000000341740141 per share, at an offering price of $5.00 per share.

View on SEC.gov

Browse all material agreements →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-22-040919

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.